Thomas DG - Search Results

1

Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.

Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Meyers PA, Priebat DA, Reinke DK, Thomas DG, Keohan ML, Samuels BL, Baker LH. Chugh R, et al. Among authors: thomas dg. J Clin Oncol. 2009 Jul 1;27(19):3148-53. doi: 10.1200/JCO.2008.20.5054. Epub 2009 May 18. J Clin Oncol. 2009. PMID: 19451433 Clinical Trial.

2

Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma.

Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L. Thomas DG, et al. Clin Cancer Res. 2002 Mar;8(3):788-93. Clin Cancer Res. 2002. PMID: 11895910

3

Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.

Mace J, Sybil Biermann J, Sondak V, McGinn C, Hayes C, Thomas D, Baker L. Mace J, et al. Cancer. 2002 Dec 1;95(11):2373-9. doi: 10.1002/cncr.11029. Cancer. 2002. PMID: 12436445 Free article.

4

Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma.

Dhaini HR, Thomas DG, Giordano TJ, Johnson TD, Biermann JS, Leu K, Hollenberg PF, Baker LH. Dhaini HR, et al. Among authors: thomas dg. J Clin Oncol. 2003 Jul 1;21(13):2481-5. doi: 10.1200/JCO.2003.06.015. J Clin Oncol. 2003. PMID: 12829666

5

Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma.

Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. Hughes DP, et al. Among authors: thomas dg. Cancer Res. 2004 Mar 15;64(6):2047-53. doi: 10.1158/0008-5472.can-03-3096. Cancer Res. 2004. PMID: 15026342

6

Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma.

Thomas DG, Giordano TJ, Sanders D, Biermann S, Sondak VK, Trent JC, Yu D, Pollock RE, Baker L. Thomas DG, et al. Cancer. 2005 Feb 15;103(4):830-8. doi: 10.1002/cncr.20847. Cancer. 2005. PMID: 15641030 Free article.

7

Primary versus radiation-associated craniofacial osteosarcoma: Biologic and clinicopathologic comparisons.

McHugh JB, Thomas DG, Herman JM, Ray ME, Baker LH, Adsay NV, Rabah R, Lucas DR. McHugh JB, et al. Among authors: thomas dg. Cancer. 2006 Aug 1;107(3):554-62. doi: 10.1002/cncr.22019. Cancer. 2006. PMID: 16795069 Free article.

8

Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines.

Mensah-Osman EJ, Thomas DG, Tabb MM, Larios JM, Hughes DP, Giordano TJ, Lizyness ML, Rae JM, Blumberg B, Hollenberg PF, Baker LH. Mensah-Osman EJ, et al. Among authors: thomas dg. Cancer. 2007 Mar 1;109(5):957-65. doi: 10.1002/cncr.22479. Cancer. 2007. PMID: 17279585 Free PMC article.

9

Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.

Chugh R, Wagner T, Griffith KA, Taylor JM, Thomas DG, Worden FP, Leu KM, Zalupski MM, Baker LH. Chugh R, et al. Among authors: thomas dg. Cancer. 2007 Jun 1;109(11):2315-22. doi: 10.1002/cncr.22669. Cancer. 2007. PMID: 17464949 Free article. Clinical Trial.

10

Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation.

Lucas DR, Kshirsagar MP, Biermann JS, Hamre MR, Thomas DG, Schuetze SM, Baker LH. Lucas DR, et al. Among authors: thomas dg. Oncologist. 2008 Apr;13(4):451-8. doi: 10.1634/theoncologist.2007-0220. Oncologist. 2008. PMID: 18448561 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

610 results

Search Page

Filters